Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer

C.J.A. Punt,V. Heinemann,T. Maughan, C. Cremolini,E. Van Cutsem,R. McDermott,G. Bodoky,T. André,P. Osterlund,A.J. Teske,P. Pfeiffer

ESMO Open（2023）

引用 0|浏览3

暂无评分

摘要

•HFS is a common toxicity of FP treatment that requires dose reductions or treatment interruptions.•CVT occurs less frequently but prevents the safe continuation of FP treatment.•S-1 is approved by European Medicines Agency for CRC patients who cannot continue FP treatment because of these toxicities.•Recommendations for use of S-1 in clinical practice are provided.

查看译文

关键词

fl uoropyrimidines,colorectal cancer,cardiotoxicity,hand-foot syndrome,S-1,recommendations

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要